Abivax price target raised to $145 from $101 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Abivax (ABVX) to $145 from $101 and keeps an Overweight rating on the shares after the company provided its 2026 corporate outlook highlighting new market research and clinical progress ahead of next week’s investment conference in San Francisco. As the firm has continued to interrogate the market opportunity for obefazimod in UC, it has found that experts are increasingly encouraged by both the magnitude of effect and tolerability profile demonstrated in the induction portion of the Phase 3 program, the analyst added.